| 1 |
Ceccato A, Russo A, Barbeta E, et al. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study[J]. Crit Care, 2021, 25(1): 432.
|
| 2 |
Bayoumy AB, de Ru JA. Sudden deafness and tuning fork tests: towards optimal utilisation[J]. Pract Neurol, 2020, 20(1): 66-68.
|
| 3 |
Shao M, Xiong G, Xiang G, et al. Sudden deafness as an initial presentation of varicella: case report and literature review[J]. Ann Palliat Med, 2021, 10(5): 5891-5896.
|
| 4 |
Furman CD, Leinenbach A, Usher R, et al. Pneumonia in older adults[J]. Curr Opin Infect Dis, 2021, 34(2): 135-141.
|
| 5 |
Baek MS, Park S, Choi JH, et al. Mortality and prognostic prediction in very elderly patients with severe pneumonia[J]. J Intensive Care Med, 2020, 35(12): 1405-1410.
|
| 6 |
彭 哲，莫运波，余 洁，等. 酚妥拉明联合亚胺培南西司他丁钠对重症肺炎患儿肺功能、炎性因子及血清sTREM-1、sICAM-1水平的影响[J]. 现代生物医学进展，2020, 20(11): 2084-2088.
|
| 7 |
Heo YA. Imipenem/Cilastatin/Relebactam: A review in gram-negative bacterial infections[J]. Drugs, 2021, 81(3): 377-388.
|
| 8 |
杨 梅，王晓玲，钱素云. 莫西沙星治疗儿童重症肺炎支原体肺炎的安全性和有效性分析[J]. 中华急诊医学杂志，2021, 30(8): 982-986.
|
| 9 |
Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19？[J]. Arch Med Res, 2020, 51(7): 741-742.
|
| 10 |
中国医师协会急诊医师分会. 中国急诊重症肺炎临床实践专家共识[J]. 中国急救医学，2016, 36(2): 97-107.
|
| 11 |
Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection[J]. BMC Pulm Med, 2019, 19(1): 179.
|
| 12 |
Losier A, Dela Cruz CS. New testing guidelines for community-acquired pneumonia[J]. Curr Opin Infect Dis, 2022, 35(2): 128-132.
|
| 13 |
Godoy MCB, Ferreira Dalla Pria HR, Truong MT, et al. Invasive Fungal Pneumonia in Immunocompromised Patients[J]. Radiol Clin North Am, 2022, 60(3): 497-506.
|
| 14 |
李旷怡，冯锦防，吴智鑫，等. 急性脑卒中患者并发重症肺炎的危险因素及病原菌分析[J]. 中国医药导报，2020, 17(19): 101-104.
|
| 15 |
陈 刚，杨 勇，罗安静，等. 亚胺培南用药现状及其与常见革兰氏阴性菌耐药性的相关性分析[J]. 新发传染病电子杂志，2021, 6(3): 225-229.
|
| 16 |
陈小英，江瑞来，梅建华. 莫西沙星联合比阿培南治疗老年人重症肺炎65例[J]. 中国基层医药，2022, 29(1): 77-81.
|
| 17 |
Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis[J]. N Engl J Med, 2021, 384(18): 1705-1718.
|
| 18 |
Greenberg RG, Landersdorfer CB, Rivera-Chaparro N, et al. Population Pharmacokinetics of Moxifloxacin in Children[J]. Paediatr Drugs, 2022, 24(2): 163-173.
|
| 19 |
Tang HJ, Wang JH, Lai CC. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia[J]. Medicine (Baltimore), 2020, 99(29): e21223.
|
| 20 |
林赴田. 金葡球菌和肺炎链球菌在体内对莫西沙星耐药性研究[J]. 中国新药杂志，2002, 11(10): 804-806.
|
| 21 |
Darvishi M, Farahani S, Haeri A. Moxifloxacin-loaded lipidic nanoparticles for antimicrobial efficacy[J]. Curr Pharm Des, 2021, 27(1): 135-140.
|
| 22 |
Amran A, Tan CY, Tan KL, et al. Pharmacokinetics and bioequivalence study of a new branded generic moxifloxacin tablet among healthy volunteers[J]. Clin Pharmacol Drug Dev, 2021, 10(12): 1514-1518.
|
| 23 |
Kondratenko SN, Zolkina IV, Shikh EV. A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods[J]. Drug Metab Pers Ther, 2020, 35(4). doi: 10.1515/dmdi-2020-0115.
|
| 24 |
Charoo NA, Abdallah DB, Parveen T, et al. Biowaiver monograph for immediate-release solid oral dosage forms: Moxifloxacin hydrochloride[J]. J Pharm Sci, 2020, 109(9): 2654-2675.
|
| 25 |
孔 菲，王 研，吴昱华. 比阿培南联合莫西沙星对重症肺炎患者疗效、炎性因子及血清CD40L、VACM-1的影响[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 533-535.
|
| 26 |
张荣嘎，夏正海，戴礼兰，等. 亚胺培南西司他丁钠联合环丙沙星治疗重症肺炎的临床效果及对血清C反应蛋白水平的影响[J]. 中国医院药学杂志，2020, 40(24): 2574-2577.
|